Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Collaboration in drug discovery can shape pharma R&D success. Explore the evidence on pharma partnerships, knowledge sharing, governance, and innovation.
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.
Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
Success for Non-Animal Testing of Preclinical Toxicity?
Can non-animal testing methods be used in preclinical drug discovery? Here is what the evidence is for their accuracy and limits assessing preclinical toxicity.
Good Laboratory Practice Always Sets the R&D Standard
Good Laboratory Practice strengthens data integrity, reproducibility, and regulatory confidence across pharma non-clinical R&D and preclinical research.